image source:mint.com
The first batch of Novavax’s COVID-19 vaccine “Covovax” production has begun in Serum Institute of India at Pune, announced by the firm.
The company shared on twitter, “A new milestone has been reached, this week we began our first batch of Covovax (a COVID-19 vaccine developed by Novavax) at our facility, here in Pune.”
A new milestone has been reached; this week we began our first batch of Covovax (a COVID-19 vaccine developed by @Novavax) at our facility, here in Pune. pic.twitter.com/FqoVTUa1nO
— SerumInstituteIndia (@SerumInstIndia) June 25, 2021
Similarly Adar Poonawalla, can also be seen sharing appreciation for Serum Institute of India team, he tweeted, “Excited to witness the first batch of Covovax (developed by Novavax) being manufactures this week at our facility in Pune.” He further adds, that the vaccine has great potential to protect our future generations below 18 years.
Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia! pic.twitter.com/K4YzY6o73A
— Adar Poonawalla (@adarpoonawalla) June 25, 2021
However, Serum Institute of India is planning to launch the Novavax’s COVID-19 vaccine “Covovax” by September as the trials are in the advance stage of completion, said by Adar Poonawalla.
Talking about the efficacy and other data of Covovax so far, the Novavax said, “the vaccine has demonstrated 93% efficacy against predominantly circulating variants.”
On June 14, in a statement Novavax stated that ‘NVX-CoV2373’ demonstrated 100 percent protection against moderate and severe Covid-19 infection- 90.4 percent efficacy overall. And it also met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.
The statement further mentioned that in United States and Mexico in order to evaluate immunogenicity, safety and efficacy of the vaccine, the study enrolled around 29,960 participants across 119 states.